{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:57:22Z","timestamp":1791381442808,"version":"4.3.3"},"reference-count":20,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Patient Care and STDs"],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:p>The tolerability of oral antiretroviral therapy (ART) administered after discontinuation of long-acting injectable (LAI) cabotegravir (CAB) + rilpivirine (RPV), during the period of residual injectables persistence, has not been described. Limited data are available on the oral ART regimens used after all-cause LAI discontinuations and on their effectiveness. This analysis was conducted in Surveillance Cohort Long-Term Toxicity of Antiretrovirals, an active, multicenter, prospective, observational pharmacovigilance cohort that monitors antiretroviral safety and development of adverse reactions. In the cohort, 75\/682 people living with HIV (PWH) discontinued LAI, the majority due to adverse events (AEs). No worsening or new AEs were observed after initiation of oral ART, even among PWH who discontinued CAB + RPV due to systemic symptoms. All patients were switched to a single-tablet regimen, with 34.7% receiving a non-nucleoside reverse transcriptase inhibitor (NNRTI)-containing regimen. Among individuals who discontinued LAI for reasons other than virologic failure (VF), all those previously on NNRTI\u2014and\/or integrase inhibitor (INSTI)\u2014based oral ART resumed regimens containing the same drug classes. After discontinuation due to VF, a protease inhibitor-based regimen was newly introduced in 4\/10 PWH. Within 6 months, HIV-RNA was \u226450 copies\/mL in 96.0% and \u2264200 copies\/mL in 98.7% of participants. The overlap between the residual CAB + RPV and the oral therapy was well tolerated; most individuals restarted their previous oral regimen, and virological suppression remained high 6 months after resuming oral ART.<\/jats:p>","DOI":"10.1177\/10872914261487462","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:14:13Z","timestamp":1789193653000},"page":"426-430","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Tolerability and Virologic Outcomes after Transition from Long-Acting Injectable ART to Oral ART"],"prefix":"10.1177","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9296-2226","authenticated-orcid":false,"given":"Marianna","family":"Giurco","sequence":"first","affiliation":[{"name":"Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Taramasso","sequence":"additional","affiliation":[{"name":"Infectious Disease Clinic, IRCCS Azienda Ospedaliera Metropolitana, Genova, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ricci","sequence":"additional","affiliation":[{"name":"Fondazione ASIA, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Squillace","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza\u2014University of Milano-Bicocca, Monza, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Ferrara","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine Unit of Infectious Diseases, University of Foggia, Foggia, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Parisini","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Galliera Hospital, Genoa, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Orofino","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, \u201cDivisione A,\u201d Amedeo di Savoia Hospital, Torino, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Menzaghi","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Lagi","sequence":"additional","affiliation":[{"name":"AOU Infectious and Tropical Diseases, Careggi Hospital, Florence, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Sarchi","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, S.Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bonfanti","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza\u2014University of Milano-Bicocca, Monza, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Biagio","sequence":"additional","affiliation":[{"name":"Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy."},{"name":"Infectious Disease Clinic, IRCCS Azienda Ospedaliera Metropolitana, Genova, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the CISAI study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003070"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000004133"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae308"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01005-1"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002466"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30068-1"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30106-5"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(16)30113-8"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.118"},{"key":"e_1_3_4_11_1","unstructured":"10.U.S. Food and Drug Administration. CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension). U.S. Food and Drug Administration: Silver Spring MD; 2025. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/212888s016lbl.pdf"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000164248.56722.3c"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.70196"},{"key":"e_1_3_4_14_1","unstructured":"13.Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2026. Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/whats-new"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/v17081108"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf184"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf025"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.70057"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00289-5"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.70128"},{"key":"e_1_3_4_21_1","unstructured":"20.Muccini C et al. Positive outcomes after discontinuing CAB+RPV LA for any reason: All people switched to STR including INSTI-based STR and 2DRs. Presented at: 33rd Conference on Retroviruses and Opportunistic Infections (CROI) 2026; Denver CO: USA. CROI: 2026; p. 531."}],"container-title":["AIDS Patient Care and STDs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10872914261487462","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10872914261487462","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10872914261487462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:26:31Z","timestamp":1791379591000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10872914261487462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11,1]]}},"alternative-id":["10.1177\/10872914261487462"],"URL":"https:\/\/doi.org\/10.1177\/10872914261487462","relation":{},"ISSN":["1087-2914","1557-7449"],"issn-type":[{"value":"1087-2914","type":"print"},{"value":"1557-7449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]}}}